No Link Between Methotrexate, Interstitial Lung Disease in RA No Link Between Methotrexate, Interstitial Lung Disease in RA
Patients with rheumatoid arthritis are at elevated risk for interstitial lung disease, but methotrexate does not accentuate that risk and may be protective, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news
NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has published two new rapid COVID-19 guidelines. (Source: NHS Networks)
Source: NHS Networks - May 18, 2020 Category: UK Health Source Type: news
COVID-19 rapid guideline: interstitial lung disease [NG177], NICE
The guideline provides clinicians with advice on how to adjust care to reduce patients ' exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic. The guideline highlights that bronchoscopy and pulmonary function tests have the potential to spread COVID-19 and they should only be carried out if the patient urgently needs them and if the results will have a direct impact on their care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 18, 2020 Category: Consumer Health News Source Type: news
European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehringer Inge...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news
VIDA Completes Second Close Of Round C Financing
CORALVILLE, Iowa, April 15, 2020 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a s... Devices, Venture Capital VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2020 Category: Pharmaceuticals Source Type: news
FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care for people ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the treatment ...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news
High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis
The first evidence-based consensus statements for systemic sclerosis-associated interstitial lung disease (SSc-ILD) recommend use of high-resolution computed tomography (CT) for screening and diagnosis, and offer guidance on when to initiate or escalate emerging treatment options.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 4, 2020 Category: Radiology Tags: Rheumatology News Source Type: news
$20 million fundraising effort will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on identifying t...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news
$20 million fundraising initiative will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on identifying t...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news
FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
The designation was supported by results from the Phase III INBUILD® study that met its primary endpoint and was recently published in the New England Journal of Medicine
RIDGEFIELD, Conn., Oct. 10, 2019 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, FDA Boehringer Ingelheim, Ofev, nintedanib, interstitial lung disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 10, 2019 Category: Pharmaceuticals Source Type: news
VIDA Expands Board, Announcing Erkan Akyuz As Independent Director
CORALVILLE, Iowa, Oct. 4, 2019 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, today announced the appointment of Erkan Akyuz as independent director. Mr. Akyuz will j... Devices, Radiology, Oncology, Personnel VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2019 Category: Pharmaceuticals Source Type: news
Nintedanib Slows Fibrosing Interstitial Lung Disease
MONDAY, Sept. 30, 2019 -- For patients with progressive fibrosing interstitial lung diseases, nintedanib is associated with a lower rate of decline in forced vital capacity (FVC) compared with placebo, according to a study published online Sept. 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves First Treatment, Ofev (Nintedanib), for ILD With Systemic Sclerosis, Scleroderma
MONDAY, Sept. 9, 2019 -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2019 Category: General Medicine Source Type: news
